DV1
DV1 is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases.
For research use only. We do not sell to patients.
- Formula: C108H170N34O26S2
- Molecular Weight:2424.85
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
SDF-1α-CXCR4 |
In Vitro
DV1 (100 nM; 30 min pre-incubation + 24 h) significantly inhibits SDF-1α-induced migration of human breast cancer MDA-MB-231 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:100 nM (pre-incubation); 100 nM (transwell culture)
-
Incubation Time:30 min (pre-incubation); 24 h (transwell culture)
-
Result:Significantly inhibited the migration of MDA-MB-231 cells toward the SDF-1α gradient (p < 0.01).
Left over 99% of migrated cells alive after 24 h of treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCRNU (female, 8 weeks old, intracranial metastatic breast cancer model via right hemisphere intracranial injection of 3×105 luciferase-expressing MDA-MB-231 cells)[2]
-
Dosage:50 μg/kg/day
-
Administration:intracerebroventricular; continuous infusion; starting on tumor cell injection day
-
Result:Detected roughly twice as many particles in tumor tissue compared to adjacent normal brain tissue, with statistically significant difference.
Reduced tumor incidence to 54.5% (n=22), with statistically significant difference from control's 83% (P=0.0361).
Resulted in smaller average tumor size in mice with tumors, though difference was not statistically significant.
Chemical Information
-
Molecular Weight 2424.85
-
Formula C108H170N34O26S2
-
Sequence
d-(Leu-Gly-Ala-Ser-Trp-His-Arg-Pro-Asp-Lys-Cys-Cys-Leu-Gly-Tyr-Gln-Lys-Arg-Pro-Leu-Pro)-NH2
-
Sequence Shortening
d-(LGASWHRPDKCCLGYQKRPLP)-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Glioma/Brain Tumor 3D Invasion Assay
The glioma/brain tumor 3D invasion assay measures outward migration and matrix invasion from multicellular tumor spheroids into a 3D extracellular matrix or organotypic brain slice. The readout is generated by time-lapse brightfield, fluorescence, confocal, or high-content imaging and quantified as invasion distance, invasion area, migration index, single-cell velocity, directionality, cumulative sprout length, or Z-direction invasion into brain tissue. Classic in vitro versions embed glioma or GBM spheroids in collagen I, Matrigel, collagen I/Matrigel, or collagen I/Matrigel/hyaluronic acid matrices, while ex vivo versions implant fluorescent GBM spheroids onto organotypic brain slices to model invasion in a preserved brain microenvironment.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Ansari S, et al. Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide. Int J Appl Basic Med Res. 2023;13(2):106-112. [Content Brief]
[2]. Krishnamurthy S, et al. Hyperosmotic intraventricular drug delivery of DV1 in the management of intracranial metastatic breast cancer in a mouse model. J Clin Neurosci. 2019;62:207-211. [Content Brief]
[3]. Zheng X, et al. Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice. Front Cell Infect Microbiol. 2017;7:175. Published 2017 May 12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DV1 Related Classifications
HY-P10427 Related Classifications
Powered by Bioz